Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hormone Profile Clear all
Enrolling by invitation Phase 2 Interventional

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

NCT03292861
View directory record Official record
Conditions
Heart Transplantation
Interventions
Thymoglobulin, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Corticosteroids
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

NCT01606709
View directory record Official record
Conditions
Endometrial Receptivity, Ovarian Hyperstimulation Syndrome
Interventions
GnRH agonist, hCG
Drug
Lead sponsor
UConn Health
Other
Eligibility
21 Years to 33 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 22, 2026, 5:10 AM EDT
Withdrawn Not applicable Interventional

Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.

NCT00720616
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Norditropin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Precision Diets for Diabetes Prevention

NCT03919877
View directory record Official record
Conditions
Pre Diabetes, Insulin Resistance, Diabetes Mellitus, Type 2
Interventions
Dietary, Oral Food Challege
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Cardiometabolic Health in Transgender Males

NCT04977765
View directory record Official record
Conditions
Transgender, Transgenderism
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
12 Years to 30 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy

NCT00805753
View directory record Official record
Conditions
Idiopathic Membranous Nephropathy
Interventions
ACTH
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

NCT00918385
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nilutamide, Dasatinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 22, 2026, 5:10 AM EDT
Completed No phase listed Observational

International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study

NCT03078036
View directory record Official record
Conditions
Breast Cancer
Interventions
Germline BRCA Test (blood), FoundationOne Dx Genomic Profile (archival Tumour Specimen), Follow-up
Genetic · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Santa Barbara, California • Denver, Colorado • Hialeah, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Testosterone Plus Finasteride Treatment After Spinal Cord Injury

NCT02248701
View directory record Official record
Conditions
Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injuries, Central Nervous System Diseases, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Interventions
Testosterone Enanthate, Finasteride, Placebo injection, Placebo pill
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

NCT05573126
View directory record Official record
Conditions
Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Interventions
EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant, Exemestane
Drug
Lead sponsor
Ellipses Pharma
Industry
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms

NCT00479778
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene/conjugated estrogens
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting Phase 1 Interventional

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

NCT06218303
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor, Selective estrogen receptor modulator (SERM)
Biological · Drug
Lead sponsor
Finn, Olivera, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Tolerance by Engaging Antigen During Cellular Homeostasis

NCT03504241
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
Interventions
Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept, sirolimus, mycophenolate mofetil, mycophenolate acid, prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 4 Interventional

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

NCT04409587
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Aspart
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 22, 2026, 5:10 AM EDT
Withdrawn Not applicable Interventional

Low Dose Growth Hormone in Obese PCOS Women

NCT00518635
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Nutropin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Progesterone in Gender Affirming Hormone Therapy Study

NCT06807580
View directory record Official record
Conditions
Transgender Women
Interventions
Placebo, Progesterone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 22, 2026, 5:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Skeletal Muscle Effects of GH in Boys

NCT04020913
View directory record Official record
Conditions
Growth Hormone Deficiency, Idiopathic Short Stature
Interventions
Somatropin injection
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
6 Years to 11 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

NCT01089569
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Insulin Glargine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study

NCT00590564
View directory record Official record
Conditions
Hepatitis C
Interventions
Sho-saiko-to
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone

NCT00137891
View directory record Official record
Conditions
Healthy
Interventions
Modified Release rhTSH
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 40 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting No phase listed Observational

Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors

NCT05611307
View directory record Official record
Conditions
Testicular Cancer, Survivorship, ASCVD, Coronary Artery Disease, Lipid Disorder, Hypogonadism, Male, Cisplatin Adverse Reaction, Bone Marrow Transplant Complications
Interventions
Lipid profile, Coronary artery assessment, Hormone levels for hypogonadism
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional

Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)

NCT00108225
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LoBag Diet - test phase, LoBAG Diet - control phase
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
55 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed Phase 3 Interventional

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

NCT00458458
View directory record Official record
Conditions
Endometriosis, Dysmenorrhea, Dyspareunia
Interventions
Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 22, 2026, 5:10 AM EDT